82 related articles for article (PubMed ID: 11847606)
1. Prognostic factors and c-erbB-2 expression in non-small-cell lung carcinoma (c-erbB-2 in non-small cell lung carcinoma).
Bakir K; Uçak R; Tunçözgür B; Elbeyli L
Thorac Cardiovasc Surg; 2002 Feb; 50(1):55-8. PubMed ID: 11847606
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.
Koutsopoulos AV; Mavroudis D; Dambaki KI; Souglakos J; Tzortzaki EG; Drositis J; Delides GS; Georgoulias V; Stathopoulos EN
Lung Cancer; 2007 Aug; 57(2):193-200. PubMed ID: 17442448
[TBL] [Abstract][Full Text] [Related]
3. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
[TBL] [Abstract][Full Text] [Related]
5. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.
Giatromanolaki A; Gorgoulis V; Chetty R; Koukourakis MI; Whitehouse R; Kittas C; Veslemes M; Gatter KC; Iordanoglou I
Anticancer Res; 1996; 16(2):987-93. PubMed ID: 8687165
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
Volm M
Anticancer Res; 1993; 13(2):375-8. PubMed ID: 8100127
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of MAPK in non-small cell lung cancer].
Zhang ZF; Ma JQ; Zhang L
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):339-42. PubMed ID: 15854513
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.
Schneider PM; Hung MC; Chiocca SM; Manning J; Zhao XY; Fang K; Roth JA
Cancer Res; 1989 Sep; 49(18):4968-71. PubMed ID: 2569928
[TBL] [Abstract][Full Text] [Related]
9. Investigation of HER2 overexpression in non-small cell lung cancer.
Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
[TBL] [Abstract][Full Text] [Related]
12. [Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis].
Liang RY; Liao ZS; Jiang SP; Zhang W; Li JG; Zheng DH
Ai Zheng; 2003 Jan; 22(1):86-90. PubMed ID: 12561444
[TBL] [Abstract][Full Text] [Related]
13. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
15. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
19. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
20. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
